There are 2137 resources available
1335P - Anti-tumour efficacy of cetuximab plus avelumab in NSCLC through induction of ADCC: Final data from CAVE-lung trial
Presenter: Morena Fasano
Session: E-Poster Display
Resources:
Abstract
1336P - Patients with EGFR exon 20 insertion mutation non-small cell lung cancer benefit from pemetrexed-based chemotherapy: A multicenter study
Presenter: Wenxian Wang
Session: E-Poster Display
Resources:
Abstract
1337P - The clincial utility of circulating free DNA (cfDNA) analysis in non-small cell lung cancer (NSCLC) in the United Kingdom
Presenter: Alastair Greystoke
Session: E-Poster Display
Resources:
Abstract
1338P - Molecular characteristics and response to immunotherapy in Chinese NSCLC patients with HER2 alterations
Presenter: Zhengbo Song
Session: E-Poster Display
Resources:
Abstract
1339P - Clinicopathological characteristics and treatment patterns observed in real-world care in patients with advanced non-small cell lung cancer (NSCLC) and KRAS G12C mutations in the Flatiron Health (FH)-Foundation Medicine (FMI) Clinico-Genomic Database (CGDB)
Presenter: Shivani Aggarwal
Session: E-Poster Display
Resources:
Abstract
1340P - Real-world treatment patterns and outcomes in patients (pts) with advanced, ALK+ non-small cell lung cancer (NSCLC) in Europe
Presenter: Nikolay Stoyanov
Session: E-Poster Display
Resources:
Abstract
1341P - Afatinib in Asian and non-Asian patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC harboring uncommon mutations
Presenter: James Chih-Hsin Yang
Session: E-Poster Display
Resources:
Abstract
1342P - Anlotinib combined with icotinib provides a promising first-line treatment option for EGFR positive NSCLC patients harboring concomitant mutations: Exploratory analysis of the ALTER-L004 study
Presenter: Diansheng Zhong
Session: E-Poster Display
Resources:
Abstract
1343P - Correlating osimertinib and erlotinib pharmacokinetics with efficacy and toxicity in EGFR-mutated NSCLC patients (START-TKI study)
Presenter: G.D. Marijn Veerman
Session: E-Poster Display
Resources:
Abstract
1344P - The impact of TP53 mutations on EGFR mt+ NSCLC IV patients treated with 3rd generation TKI on second-line or further line therapy: Real world data from the German CRISP registry
Presenter: Markus Falk
Session: E-Poster Display
Resources:
Abstract